Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study
Language English Country England, Great Britain Media print
Document type Journal Article, Multicenter Study
PubMed
39605286
DOI
10.1093/ecco-jcc/jjae182
PII: 7911900
Knihovny.cz E-resources
- Keywords
- Inflammatory bowel disease, JAK inhibitors, children,
- MeSH
- C-Reactive Protein analysis MeSH
- Child MeSH
- Heterocyclic Compounds, 3-Ring * therapeutic use adverse effects MeSH
- Remission Induction methods MeSH
- Induction Chemotherapy methods MeSH
- Leukocyte L1 Antigen Complex analysis MeSH
- Humans MeSH
- Adolescent MeSH
- Retrospective Studies MeSH
- Colitis, Ulcerative * drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Names of Substances
- C-Reactive Protein MeSH
- Heterocyclic Compounds, 3-Ring * MeSH
- Leukocyte L1 Antigen Complex MeSH
- upadacitinib MeSH Browser
BACKGROUND AND AIMS: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U. METHODS: In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction. RESULTS: One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologics. At the end of the 8-week induction period, clinical response, clinical remission, and corticosteroid-free clinical remission (CFR) were observed in 84%, 62%, and 56% of the children, respectively. Normal C-reactive protein and fecal calprotectin (FC) <150 mcg/g were achieved in 75% and 50%, respectively. Combined CFR and FC remission was observed in 18/46 (39%) children with available data at 8 weeks. Adverse events were recorded in 37 children, including 1 serious AE of an appendiceal neuroendocrine tumor. The most frequent AEs were hyperlipidemia (n = 13), acne (n = 12), and infections (n = 10, 5 of whom with herpes viruses). CONCLUSIONS: Upadacitinib is an effective induction therapy for refractory pediatric UC and IBD-U. Efficacy should be weighed against the potential risks of AEs.
Al Jalila Children's Specialty Hospital Dubai United Arab Emirates
Biomedical Research Centre University of Oxford Oxford UK
Centre of Human Genetics University of Oxford Oxford UK
Children's Hospital Zagreb University of Zagreb Medical School Zagreb Croatia
Department of Paediatric and Adolescent Medicine Akershus University Hospital Lørenskog Norway
Department of Paediatrics University of Oxford Oxford UK
Department of Pediatrics 1 Medical University Innsbruck Innsbruck Austria
Department of Pediatrics School of Medicine Kyungpook National University Daegu Korea
Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel
Faculty of Medicine Tel Aviv University Tel Aviv Israel
Gastroenterology and Nutrition Unit Meyer Children's Hospital Florence Italy
Institute for Maternal and Child Health IRCCS Burlo Garofolo Trieste Italy
Pediatric Department Children's Hospital Vittore Buzzi University of Milan Milan Italy
Pediatric Hepatology Gastroenterology and Transplantation ASST Papa Giovanni XXIII Bergamo Italy
Seattle Children's Hospital IBD Center Seattle WA USA
Translational Gastroenterology Unit University of Oxford Oxford UK
References provided by Crossref.org